{"entity":{"id":"nct05270044","kind":"trial","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","aka":[],"tldr":"A phase 3 trial of Encorafenib, Binimetinib in melanoma, run by Pierre Fabre Medicament, active and no longer recruiting.","summary":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. is a phase 3 interventional study registered as NCT05270044 by Pierre Fabre Medicament, with 815 participants planned, started 2022-05-02 and due to reach its primary completion in 2027-03-31. Interventions recorded: Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05270044","url":"https://clinicaltrials.gov/study/NCT05270044"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["encorafenib","binimetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05270044","phase":"3","setting":"Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group","sponsor":"Pierre Fabre Medicament","enrolled":815,"outcomes":[]},"route":"/trials/nct05270044/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}]}}